WallStSmart

Novo Nordisk A/S (NVO)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1680% more annual revenue ($309.06B vs $17.36B). NVO leads profitability with a 33.1% profit margin vs 8.6%. UHS appears more attractively valued with a PEG of 1.29. UHS earns a higher WallStSmart Score of 76/100 (B+).

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08

UHS

Strong Buy

76

out of 100

Grade: B+

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.5
Piotroski: 6/9Altman Z: 2.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued
UHSUndervalued (+78.6%)

Margin of Safety

+78.6%

Fair Value

$1081.08

Current Price

$186.72

$894.36 discount

UndervaluedFair: $1081.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

UHS4 strengths · Avg: 8.8/10
P/E RatioValuation
8.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

EPS GrowthGrowth
42.7%8/10

Earnings expanding 42.7% YoY

Areas to Watch

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Return on Equity, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

NVO profiles as a declining stock while UHS is a value play — different risk/reward profiles.

UHS carries more volatility with a beta of 1.26 — expect wider price swings.

UHS is growing revenue faster at 9.1% — sustainability is the question.

UHS generates stronger free cash flow (293M), providing more financial flexibility.

Bottom Line

UHS scores higher overall (76/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?